Global footprint Leverage Jubilant Life Sciences’ diversified manufacturing capabilities across APIs, solid dosage forms, radiopharmaceuticals, and contract manufacturing to position cross-sell opportunities for integrated pharma solutions in regulated markets (US, India, Canada) and support their 50+ US-based radiopharmacies network.

Expansion leverage Target growth opportunities around their recent asset acquisitions and capacity expansions, such as pyridine production assets from Solvay and new or expanded manufacturing capabilities, to present premium, scalable API and specialty intermediate supply solutions for pharmaceutical partners.

R&D collaboration Exploit Jubilant’s Drug Discovery Solutions and in-house innovation centers to propose joint research programs, out-licensing deals, or early-access partnerships for novel compounds, analytical services, and high-value discovery platforms.

Digital enablement Engage with their tech stack and digital platforms (Power Automate, Tableau, Azure, Jira) to offer data-driven collaboration solutions, integrated supply-chain analytics, and digital QA/automation services that enhance efficiency across global manufacturing and project workflows.

Strategic partnerships Position Jubilant as a preferred partner of choice for contract manufacturing and life science ingredients by highlighting capabilities in sterile and non-sterile manufacturing, radiopharmaceuticals, and specialty intermediates to attract OEMs, CDMOs, and multinational pharma players seeking integrated supply chains.